Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD229 CAR T cells are genetically engineered T-cell therapies designed to target CD229 (also known as Ly9 or SLAMF3), a cell-surface receptor belonging to the signaling lymphocytic activation molecule (SLAM) family. CD229 is highly and uniformly expressed on malignant plasma cells in multiple myeloma, including myeloma stem cells, as well as on various B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma, chronic lymphocytic leukemia (CLL), and follicular lymphoma. Developed by researchers at the University of Utah and the University of Maryland, CD229 CAR T cells utilize an anti-CD229 single-chain variable fragment (scFv) coupled with intracellular signaling domains (such as CD3ζ and 4-1BB) to selectively bind and eliminate CD229-expressing tumor cells. Preclinical studies have demonstrated potent cytotoxicity against multiple myeloma and B-cell malignancies, including activity against CD19-deficient tumor cells, suggesting potential utility in patients who relapse after CD19-targeted CAR T-cell therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CD229 CAR T cells.
Work on CD229 CAR T cells? Claim this page to correct or add information. Claim this page